Evidence map›Paper›PMID 38676903›Full record

ReviewJournal of gastrointestinal cancer2024

Pathological Complete Response Achieved with XELOX Chemotherapy, HIPEC, and Anti-PD-1 Immunotherapy in Stage IV Gastric Adenocarcinoma with Peritoneal Metastasis: A Case Report and Review of the Literature.

Jiajie Zhou, Jie Wang, Wei Wang, Longhe Sun, Shuai Zhao, Qiannan Sun, Daorong Wang

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Journal of gastrointestinal cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jiajie Zhou *Northern Jiangsu People's Hospital , Clinical Teaching Hospital of Medical School, Nanjing University, Yangzhou, 225001, China.
Jie Wang *Clinical Medical College, Yangzhou University, Yangzhou, 225001, China.
Wei WangNorthern Jiangsu People's Hospital, Yangzhou, 225001, China.
Longhe SunClinical Medical College, Yangzhou University, Yangzhou, 225001, China.
Shuai ZhaoNorthern Jiangsu People's Hospital , Clinical Teaching Hospital of Medical School, Nanjing University, Yangzhou, 225001, China.
Qiannan SunNorthern Jiangsu People's Hospital, Yangzhou, 225001, China.
Daorong WangNorthern Jiangsu People's Hospital , Clinical Teaching Hospital of Medical School, Nanjing University, Yangzhou, 225001, China. wdaorong666@sina.com.
Northern Jiangsu People's Hospital · CNTaizhou People's Hospital · CNYangzhou University · CN

Funding

National Natural Science Foundation of China NO. 82373014
6 · The paper itself

Abstract

backgroundThe detection rates of early gastric cancer (GC) in China are approximately 20%; upon diagnosis, the majority of patients with GC are identified as having advanced stage disease, and in some cases, even metastatic advanced GC. Currently, the optimal treatment strategy for peritoneal metastasis (PM) in GC remains uncertain, and pathological complete response (pCR) is rare following conversion therapy. CASE PRESENTATION: This case report details the management of a 66-year-old patient diagnosed with advanced stage IVB (T4N2M1c) adenocarcinomas of the gastric cardia with PM who received multimodal therapy comprised of hyperthermic intraperitoneal chemotherapy (HIPEC), XELOX chemotherapy, and anti-programmed cell death-1 (PD-1) therapy followed by radical gastrectomy. Through the multimodal management, the patient attained PCR and experienced long-term survival.

conclusionThe conversion therapy protocol combined with HIPEC, XELOX chemotherapy, and anti-PD-1 therapy and our scientific, accurate, full-course management strategy may be propagable for potentially curing patients with advanced GC with PM.

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsCapecitabineHyperthermic Intraperitoneal ChemotherapyOxaloacetatesPeritoneal NeoplasmsStomach NeoplasmsAgedCombined Modality TherapyFluorouracilGastrectomyHumansImmune Checkpoint InhibitorsMaleNeoplasm StagingProgrammed Cell Death 1 ReceptorCapecitabineFluorouracilImmune Checkpoint InhibitorsOxaloacetatesPDCD1 protein, humanProgrammed Cell Death 1 ReceptorAdvanced gastric cancerHIPECMultimodal therapyPathological complete responsePeritoneal metastasis

Identifiers

PMID38676903
OpenAlexW4395701767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.